Intravenous thrombolysis in ischemic stroke: clinical predictors of efficacy and safety
Introduction. Systemic thrombolysis with recombinant tissue plasminogen activator is the gold standard of reperfusion therapy, having the maximum level of evidence in European and North American guidelines for the treatment of patients with acute ischemic stroke (IS). Objective: to determine factors...
Main Authors: | Maksim A. Domashenko, Marina Yu. Maksimova, Marine M. Tanashyan |
---|---|
Format: | Article |
Language: | English |
Published: |
Research Center of Neurology
2019-03-01
|
Series: | Анналы клинической и экспериментальной неврологии |
Subjects: | |
Online Access: | https://annaly-nevrologii.com/journal/pathID/article/viewFile/573/460 |
Similar Items
-
The mechanisms of reperfusion during in stroke patients treated with intravenous thrombolysis
by: Maksim Alekseyevich Domashenko, et al.
Published: (2012-12-01) -
Benefit and risk of early intravenous heparin after thrombolysis in patients with acute ischemic stroke
by: Xu Tong, et al.
Published: (2020-10-01) -
Intravenous thrombolysis in acute ischemic stroke
by: M. A. Domashenko, et al.
Published: (2017-02-01) -
Intravenous Thrombolysis for Embolic Stroke due to Cardiac Myxoma
by: Mu-Chien Sun, et al.
Published: (2011-01-01) -
Intravenous Thrombolysis Prior to Mechanical Thrombectomy in Acute Ischemic Stroke: Silver Bullet or Useless Bystander?
by: Federico Di Maria, et al.
Published: (2018-09-01)